Home

Menu

Loading wiki pages...

View
Wiki Version:
Abstract: Background/Objectives: With disproportionately high rates of opioid overdose mortality and opioid use disorder (OUD), Medicare beneficiaries with disabilities are an important population to engage in treatment. This study examined racial/ethnic disparities in buprenorphine initiation after a new OUD diagnosis in this priority population. Methods: This longitudinal, retrospective cohort study used national data from a 20% random sample of Medicare beneficiaries from 2016-2018. The sample included individuals with eligibility due to disability and 12 months of continuous enrollment in Parts A, B, and D who had a new OUD diagnosis (i.e., no diagnosis in the prior 180 days) and a known race/ethnicity (N= 181,796). Buprenorphine initiation was measured as a filled prescription within 30 and 180 days of the index diagnosis. Claims data were linked with the Area Health Resources File and the Medicare Part D Prescriber Public Use Files to measure county-level Medicare buprenorphine prescriber availability, proportion of White residents, and median household income. Outcomes were estimated using multilevel logistic regression accounting for county-level clustering and adjusting for individual and county-level covariates. Results: Black (aOR=0.37; p<0.01), Asian/Pacific Islander (aOR=0.41; p<0.01), Hispanic/Latinx (aOR=0.58; p<0.01), and American Indian/Alaskan Native (aOR=0.68; p<0.01) beneficiaries had significantly lower odds of receiving buprenorphine within 30 days of an index diagnosis compared with their White counterparts. Similar patterns were observed for the 180-day outcome, and estimates remained significant after adjusting for county-level measures. Buprenorphine initiation within 30 days of an index diagnosis was significantly associated with higher county-level rates of Medicare buprenorphine prescribers (aOR=1.13; p<0.01), and a higher proportion of White residents (aOR=5.15; p<0.01). Conclusions: Racial/ethnic disparities in timely receipt of buprenorphine after a new OUD diagnosis highlight the need to increase access to care for disadvantaged groups. Interventions that increase buprenorphine prescribing and Medicare participation with a focus minority-majority counties may improve treatment equity.
OSF does not support the use of Internet Explorer. For optimal performance, please switch to another browser.
Accept
This website relies on cookies to help provide a better user experience. By clicking Accept or continuing to use the site, you agree. For more information, see our Privacy Policy and information on cookie use.
Accept
×

Start managing your projects on the OSF today.

Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.